La cadena de opciones muestra datos clave de las opciones de acciones de Jin Medical International a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Jin Medical International..

Jin Medical International (NASDAQ:ZJYL) Bolsa, Cadena de Opciones

Jin Medical International

Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company's products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International Ltd

Advanced optical infrastructure delivers 20T capacity, automated management on 1,055 km Jakarta-Singapore link
PLANO, Texas, April 22, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4409361-1&amp;h=2622403139&amp;u=https%3A%2F%2Fwww.rbbn.com%2F&amp;a=Ribbon+Communications+Inc.">Ribbon Communications Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>), a leading supplier of real-time communications technology and IP optical networking solutions, today announced that PT Mora Telematika Indonesia Tbk ("Moratelindo") (IDX: MORA), one of Indonesia's largest telecommunication infrastructure and network providers, through Ribbon's local partner, has selected Ribbon's cutting edge technology solutions to fulfill their growing requirements for reliable, high capacity connectivity and seamless, automated infrastructure management. Ribbon is dedicated to assisting the world's largest service providers, enterprises and critical infrastructure operators in modernizing and safeguarding their networks and services.

News

RBBN

Ribbon Communications Chosen By Moratelindo For Enhanced Submarine Network Capabilities

Rigetti, in collaboration with Riverlane and the National Quantum Computing Centre (NQCC), has been selected as one of the winners of Innovate UK's Quantum Missions pilot competition. Leveraging Rigetti's quantum computer hosted at the NQCC, the £3.5 million Rigetti-led consortium aims to benchmark and enhance the quantum error correction capabilities of superconducting quantum computers — a requirement for achieving large-scale fault-tolerant quantum computing.

Contracts

RGTI

Rigetti Wins Innovate UK's Quantum Missions Pilot Competition; To Lead £3.5M Consortium Alongside Riverlane And The NQCC Superconducting Circuits Team

Earnings

ASRV

AmeriServ Financial Q1 EPS $0.12 Up From $0.11 YoY, Sales $14.05M Up From $13.69M YoY

SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture, LLC's contract manufacturing partner, Saptalis Pharmaceuticals, LLC for ArbliTM has indicated to Scienture that Saptalis has the materials and capabilities to produce the batches and supply product inventory in time for the target commercial launch. In addition, Scienture, LLC has also entered into agreements with strategic partners for warehousing and distributing the product to the market through various wholesalers.
ArbliTM is meant for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes. ArbliTM is the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market.
ArbliTM is a novel proprietary formulation of losartan, a proven therapy for treating hypertension, which provides a tailored approach to patients that require or prefer an oral liquid option of losartan. Appropriate dosing is now easier, safe and effective, while providing the assurance of quality as an FDA-approved product. ArbliTM provides a safe and convenient option to patients requiring a liquid formulation and addresses the intrinsic risks associated with potential inconsistencies in the process of crushing tablets to extemporaneously compound losartan prescriptions. ArbliTM has two issued patents from the USPTO, which are also expected to be listed in the FDA Orangebook.
Losartan is classified as an angiotensin receptor blocker (ARB) for treating hypertension and is one of the highest prescribed molecules for this indication. Current products in the market containing losartan are available only as oral solids, which can be further compounded to a liquid formulation. ArbliTM is the first liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. IQVIA data (MAT December 2024) indicates a total annual sales of approximately $292 million and a prescription volume of 68 million (TRx) for losartan in the US market.

Biotech

General

SCNX

Scienture Announces Manufacturing Launch Activities For Arbli Through Subsidiary Scienture, In Collaboration With Saptalis Pharmaceuticals And Strategic Distribution Partners, Targeting July 2025 Commercial Launch

Stephens &amp; Co. analyst Matt Olney reiterates Cadence Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) with a Overweight and maintains $40 price target.

Price Target

Reiteration

Analyst Ratings

CADE

Stephens & Co. Reiterates Overweight on Cadence Bank, Maintains $40 Price Target

Fartcoin (CRYPTO: FARTCOIN) has surged past the key $1 milestone, eclipsing better-known meme coins and catching the eye of <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41879587/from-16000-to-18-million-in-unrealized-gainsmillionaire-bonk-doge-trader-shares-update-if-you-cant-hold-you-wont-be-rich">top traders across the space</a>. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Fartcoin (CRYPTO: FARTCOIN)</td>
<td>$1.06</td>
<td>$1.06 billion</td>
<td>+17.9%&nbsp;</td>
<td>+17%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1645</td>
<td>$24.5 billion</td>
<td>+2.4%</td>
<td>+3.3%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001259</td>
<td>$7.4 billion</td>
<td>+0.1%&nbsp;</td>
<td>+5.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Prominent trader Unipcs <a href="https://x.com/theunipcs/status/1914506572857827360">shared</a> that his Fartcoin long now sits at $5.1 million in profit, up from $3.2 million as of April 9. 
Heavily-followed crypto expert Joe McCann <a href="https://x.com/joemccann/status/1914416997812854968">called</a> Fartcoin the &#8220;best-looking chart in crypto right now,&#8221; while pseudonymous trader Cold Blooded Shiller <a href="https://x.com/ColdBloodShill/status/1914587407992619049">noted</a> it has cleared a four-month downtrend, confirming its first full trend reversal since January 2025.
Altcoin Sherpa set his next upside target at $1.30, although he cautioned traders to expect brief pauses or consolidations along the way. 
Despite ranking 62 by market cap, Sherpa believes Fartcoin has significant upside potential due to its rising brand recognition.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">$1.30 is next with a few pauses along the way imo for Fartcoin This is still pretty low market cap wise at #62, I think it still has a few x left given the mindshare <a href="https://t.co/3RjhyRNnXJ">pic.twitter.com/3RjhyRNnXJ</a>
&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1914615221941100701?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Dead Cat Bounce <a href="https://x.com/DCBcrypto/status/1914596430741746085">provided </a>a technical breakdown, noting Fartcoin initially failed to break its range high at the yearly open and started forming lower highs. 
But it defied broader market weakness, ultimately breaking above the range and validating a bullish breakout. 
He managed to secure a spot position on the retest, calling the chart "strong" as long as it holds above prior resistance.
Statistics: According to Grey BTC, whale accumulation <a href="https://x.com/greybtc/status/1914602482619081086">continues</a>, with one wallet scooping up $3.07 million worth of Fartcoin.
Fartcoin's 16% single-day rally brought it above $1 for the third time ever, something Dogecoin and Shiba Inu still haven&#8217;t achieved. 
Standing strong in 24-hour trading volume at the fourth position, Fartcoin has left behind Shiba Inu, Dogwifhat, Bonk and many others.
Over the past 30 days, Fartcoin is up 112.8%, while Dogecoin and Shiba Inu have posted negative returns.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44901647/not-dogecoin-shiba-inu-heres-why-whales-are-piling-into-fartcoin">Not Dogecoin, Shiba Inu — Here&#8217;s Why Whales Are Piling Into Fartcoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Dogecoin, Shiba Inu Struggle As Fartcoin Surges Past $1

U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Tuesday.
Shares of Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) shares fell sharply in today&#8217;s pre-market trading after the company reported worse-than-expected first-quarter EPS and revenues. The company also lowered its <a href="https://www.benzinga.com/quote/NOC/earnings">FY25 EPS guidance</a>.
Northrop Grumman reported quarterly earnings of $6.06 per share which missed the analyst consensus estimate of $6.26 per share. The company reported quarterly sales of $9.468 billion which missed the analyst consensus estimate of $9.936 billion.
Northrop Grumman shares tumbled 8.5% to $485.99 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) shares dipped 9.3% to $10.65 in pre-market trading. USA Rare Earth will release financial results for the first quarter, after the closing bell on Wednesday, May 14.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) declined 7.3% to $8.40 in today's pre-market trading.</li>
<li>National Energy Services Reunited Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) dipped 6.9% to $5.60 in pre-market trading.</li>
<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) declined 6.1% to $9.81 in pre-market trading.</li>
<li>SITE Centers Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) shares fell 5.7% to $11.01 in pre-market trading.</li>
<li>Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) declined 5.7% to $20.67 in pre-market trading following first-quarter results.</li>
<li>Five Point Holdings, LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FPH#NYSE">FPH</a>) declined 5.3% to $4.61 in pre-market trading. Five Point Holdings will hold a conference call to discuss its first quarter financial results on Thursday, April 24.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

CELC

NESR

SITC

TYRA

USAR

Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<a href="https://www.globenewswire.com/Tracker?data=yfZ2eSHDjFlismVQ22s7M9ahGIsxc_c3JjmLemcisJobsa7peXhySiz3DFrXLtooq_g_f-kPedb-852zUon7n4qfGS2joB0T27fsCeHHKYYtw-aQJo35C-X1FD-BX-FCvZKlVgEPP51WycSwzCraxE1fTU-LuVNL9f5gb1jMK_KlfH7jsUwMxcGVsDdKfbInO7SPuLXztF4TCyZm3-Hv7-SU6ahOnQyaTE3rbNNQK5z7ZGUaeN9zQncx-ehsALJgmYNDdESneNf5OfsvcU8U-V3wN1JkJaKsPN9NYHEEpn0P3cC8zJB6CXCLVVSVPrXhKTAQWCCT41fQ4Y75_sB5364FIFW_kWoJF0Nxt6gjl-aTyM8QDlzBZ4lIyPwMj960SXfgwL2CMfNxSm9lWOuz5Fm8GCIYi29ve90WTSwBYLs=">Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting <a href="https://www.globenewswire.com/Tracker?data=2Ap9Z7U3HayJzgEw3tx13uO0r3yrphLjM4Fi4nyTVJEqF6LUdjUxq6W1UgaoCpDR75nPmjcAH8gb-akQ4d42b5HGP6n3FFxu1Qkm-WC59rkA-ng-syij9rLfgJySEkoIxhNkLegX__IsPydEZJE4NlyR2eXOPVvZOiUgxwB7AGnX2GiO65WX8MFHRXhdOEHFA3Dzvy-sBaE9Sn_-1m20PCjJDQaFHfLkGEPIZMSXjt3YHpCw2DMICI9FQYGVK_G907DW4sbDJM7sE6WUQhC2jzuivj8nFSylTCkdzLzgt45ZRPJL8w-PMf4g7QEEJ7CE">Activin E, which was discovered using iBio's patented Machine-Learning Antibody Engine</a>. Activin E is a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease. iBio plans to rapidly advance testing of the antibody in more complex models following preclinical studies that demonstrated strong antibody binding, inhibition of Activin E signaling and fat-specific weight loss in an obese rodent animal model.
The in-licensed antibody represents what iBio believes to be the first functional inhibitor of Activin E, a challenging, yet genetically validated therapeutic target playing a key role in regulating energy balance and fat distribution. Inhibiting Activin E-mediated signaling could offer a novel therapeutic strategy to reduce internal abdominal fat while preserving muscle mass—potentially reversing obesity, preventing diabetes, and improving overall cardiometabolic health. As one of several cellular components involved in cardiometabolic regulation, Activin E, along with amylin, GLP-1 and others, are part of a broader network of signaling pathways that have the potential to be targeted simultaneously to yield synergistic benefits for patients.
Using its proprietary Machine Learning Antibody Engine and advanced epitope engineering technology, iBio designed engineered epitopes representing five key regions of the Activin E protein. This approach led to the successful development of a molecule that fully blocks Activin E-mediated signaling and inhibits its function across multiple in vitro models. In vivo proof-of-concept was established in a rodent model of obesity, where the antibody induced fat-selective weight loss as a monotherapy and showed synergistic weight loss when added to a GLP-1 receptor agonist in <a href="https://www.globenewswire.com/Tracker?data=IC6CnWZUDTXt2k2kQcI4UJS1sr27bCIdXB-9lKCH8hUbHT9eSX6RDqG0dYhVJoP0JKTOGoC1X4gdoMxNyQ8ynAHTRfFgqQKESrJ9tavPegKHu6w_bc9eAAY8NIS3PlJpiOr4wMu1FUImPpFwVI8vsHJnGXMEZTaiaFlygE1a550MScR6WC_Is1iLv-scMHL1eGjJQKeszBIQMEDM0twrdJ-WOs-WEx9vGSAr96a0bJg=">recently published data</a> by iBio. iBio plans to present additional preclinical data of its antibody targeting Activin E at the International BMP Conference, taking place in Philadelphia, PA, from May 2–6.
"Our decision to license this Activin E-targeting functional antibody, a potentially first-in-class molecule, at this early stage reflects our firm belief in Activin E as a promising therapeutic target and our confidence in building upon the strong preclinical data we recently published," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "This antibody represents a strategic expansion of our pipeline in cardiometabolic diseases and obesity and a significant step toward clinical development of a medication that can potentially offer meaningful benefits to patients."

IBIO

iBio, Announces A Licensing Agreement With Astralbio For A Preclinical First-In-Class Antibody Targeting Activin E

Fully Virtual Event Scheduled for June 27, 2025
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54240283&amp;newsitemid=20250422494799&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=4799d27d578473dc9ce41dd3ef438365">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.christopherreeve.org%2F&amp;esheet=54240283&amp;newsitemid=20250422494799&amp;lan=en-US&amp;anchor=Christopher+%26amp%3B+Dana+Reeve+Foundation&amp;index=2&amp;md5=768a206510831e902e4cb558fc0af8ca">Christopher &amp; Dana Reeve Foundation</a>, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.scisymposium.com&amp;esheet=54240283&amp;newsitemid=20250422494799&amp;lan=en-US&amp;anchor=3rd+Annual+Spinal+Cord+Injury+Investor+Symposium&amp;index=3&amp;md5=99f24f2f1e3c2e4fa81acd2e45ab6212">3rd Annual Spinal Cord Injury Investor Symposium</a> ("3rd SCIIS"). This year's event aims to bring together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations and the investment community, in order to discuss perspectives on current and future treatments, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and importantly, broaden awareness of and investment capital into SCI. The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025.

LCTX

Lineage Cell Therapeutics And Christopher & Dana Reeve Foundation To Collaborate And Present 3Rd Annual Spinal Cord Injury Investor Symposium

AUBN

Auburn National Bancorp Q1 EPS $0.44 Up From $0.39 YoY, Sales $7.79M Up From $7.54M YoY

Wells Fargo analyst Zachary Fadem maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Equal-Weight and raises the price target from $420 to $445.

Wells Fargo Maintains Equal-Weight on Domino's Pizza, Raises Price Target to $445

Baird analyst David George maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Outperform and lowers the price target from $80 to $75.

Baird Maintains Outperform on Comerica, Lowers Price Target to $75

Sunrise Realty Trust, Inc. ("SUNS" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>), a commercial real estate lender on the Tannenbaum Capital Group ("TCG") Real Estate platform, today provided a preliminary estimate of distributable earnings for the quarter ended March 31, 2025, and disclosed other portfolio level information.
Distributable Earnings &amp; Book Value Per Share
SUNS' preliminary estimate of distributable earnings for the quarter ended March 31, 2025 is $0.30 to $0.32 per basic weighted average common share. This compares to distributable earnings of $0.30 for the quarter ended December 31, 2024. In addition, SUNS disclosed that it expects its book value per share to be $13.60 - $13.90 per share.
Portfolio and Originations
During the quarter ended March 31, 2025, the TCG Real Estate platform originated $212.5 million of loans, of which SUNS committed $147.5 million and funded $109.8 million of new and existing loans. As of March 31, 2025, the SUNS portfolio had $352.1 million of commitments with $233.4 million funded. As of April 18, 2025, the SUNS portfolio has $352.1 million of commitments with $235.4 million funded. Currently, the TCG Real Estate Platform has two signed, non-binding term sheets totaling $100 million in documentation, of which we expect SUNS to be allocated a portion.

Guidance

SUNS

SUNS' Preliminary Estimate Of Distributable Earnings For The Quarter Ended March 31, 2025 Is $0.30-$0.32 Per Basic Weighted Average Common Share; SUNS Disclosed That It Expects Its Book Value Per Share To Be $13.60-$13.90 Per Share

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has reportedly pivoted its marketing for the Cybertruck as Elon Musk's EV giant rebrands the vehicle to showcase its utilitarian quotient.
What Happened: Targeting a more traditional pick-up truck marketing approach for the vehicle, Tesla has reworked the Cybertruck's page on the official website. The website now features visuals of the Cybertruck hauling construction material and a trailer, family outings, as well as visuals of the vehicle on rugged terrains — all activities one would expect a pick-up truck owner to do, <a href="https://www.businessinsider.com/tesla-cybertruck-revamp-working-man-f-150-2025-4">reported </a>Business Insider on Tuesday.
This is in stark contrast to the previous strategy, which showcased the Cybertruck as a futuristic vehicle with visuals of other planets like Mars. The report mentioned how the company has moved to position the Cybertruck to be &#8220;less DeLorean, more Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) F-150.&#8221;
However, the shift in approach may be difficult to put into practice. "Pitching it to truck people is more about the functionality,&#8221; an anonymous Tesla salesperson told the publication.
The salesperson also shared how traditional truck customers ask about the Cybertruck's towing capabilities as well as how much it can haul in the bed. Cybertrucks have been criticized for a lack of ruggedness in the past.
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: The shift in strategy comes in as Tesla has <a href="https://www.benzinga.com/markets/equities/25/04/44755221/tesla-unveils-new-cybertruck-long-range-trim-with-a-362-mile-range-and-reduced-features">released a cheaper version </a>of the Cybertruck priced at $62,490 with the Federal EV credit, as the company looks to boost <a href="https://www.benzinga.com/tech/25/04/44857987/tesla-experiences-151-decline-in-new-vehicle-registrations-in-california-report">dwindling sales figures</a> and appeal to a wider customer base.
Recently, Tesla properties like Superchargers as well as vehicles like the Cybertruck have been <a href="https://www.benzinga.com/trading-ideas/25/04/44829030/tesla-owners-face-new-challenge-amid-tariffs-vandalism-insurance-costs-going-up-twice-the-national-rate">subject to vandalism</a> in the U.S., which coincides with Musk's endorsement of right-wing political ideals and increasing involvement with the Trump administration.
Elsewhere, while Tesla still dominates the <a href="https://www.benzinga.com/25/04/44755934/us-q1-ev-sales-data-shows-106-yoy-growth-tesla-experiences-decline-but-still-dominates-domestic-ev-sales">domestic U.S. EV sector</a>, other brands are catching up with Musk's company, according to sales data, which shows an increase in adoption of EVs among drivers in the U.S.
Price Action: TSLA has experienced a 40.04% YTD decline in stock value. It currently trades for $227.42, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44915873/tesla-settles-lawsuit-over-fatal-2021-crash-involving-model-y">Tesla Settles Lawsuit Over Fatal 2021 Crash Involving Model Y</a></li>
</ul>
Image Via Shutterstock

Tech

TSLA

Cybertruck Gets A Down-To-Earth Redesign As Tesla Shifts To Traditional Pickup Marketing Amid Poor Sales

Stephens &amp; Co. analyst Matt Olney reiterates BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) with a Equal-Weight and maintains $124 price target.

BOKF

Stephens & Co. Reiterates Equal-Weight on BOK Financial, Maintains $124 Price Target

<h3>Gainers</h3>
<ul>
<li>Sohu.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHU#NASDAQ">SOHU</a>) stock moved upwards by 27.6% to $10.95 during Tuesday's pre-market session. The market value of their outstanding shares is at $361.7 million. </li>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) stock moved upwards by 14.34% to $2.95. The market value of their outstanding shares is at $2.4 million. </li>
<li>Starbox Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) stock increased by 14.28% to $2.16. The market value of their outstanding shares is at $1.1 million. </li>
<li>TEN Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHLD#NASDAQ">XHLD</a>) shares increased by 12.23% to $0.77. The company's market cap stands at $21.6 million. </li>
<li>WiMi Hologram Cloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIMI#NASDAQ">WIMI</a>) stock moved upwards by 9.77% to $4.94. The market value of their outstanding shares is at $48.5 million. </li>
<li>Scholastic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCHL#NASDAQ">SCHL</a>) shares increased by 9.62% to $17.99. The market value of their outstanding shares is at $480.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) shares fell 19.0% to $3.25 during Tuesday's pre-market session. The company's market cap stands at $81.4 million. </li>
<li>Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) stock declined by 12.77% to $0.51. The company's market cap stands at $9.7 million. </li>
<li>ATN International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) stock declined by 8.57% to $16.01. The market value of their outstanding shares is at $247.8 million. </li>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock declined by 7.91% to $0.11. The company's market cap stands at $1.6 million. </li>
<li>Arena Group Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AREN#AMEX">AREN</a>) stock fell 6.04% to $2.49. The market value of their outstanding shares is at $118.4 million. </li>
<li>TruGolf Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>) stock declined by 4.95% to $0.24. The company's market cap stands at $7.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHL

AREN

ATNI

BLMZ

DRCT

GAIA

SCHL

SOHU

STBX

TRUG

WIMI

XHLD

12 Communication Services Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares increased by 371.1% to $4.24 during Tuesday's pre-market session. The market value of their outstanding shares is at $40.0 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock increased by 59.0% to $0.06. The company's market cap stands at $10.5 million. </li>
<li>Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) shares rose 28.52% to $3.65. The company's market cap stands at $138.0 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock rose 20.99% to $0.28. The market value of their outstanding shares is at $7.2 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock rose 20.31% to $1.02. The market value of their outstanding shares is at $10.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 16.66% to $1.19. The company's market cap stands at $16.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock declined by 22.9% to $0.1 during Tuesday's pre-market session. </li>
<li>Sionna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SION#NASDAQ">SION</a>) stock fell 17.53% to $9.32. The company's market cap stands at $409.9 million. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) shares fell 16.74% to $8.31. The market value of their outstanding shares is at $147.2 million. </li>
<li>Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) stock decreased by 16.01% to $7.61. The market value of their outstanding shares is at $404.0 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock fell 13.96% to $0.14. The market value of their outstanding shares is at $3.8 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock declined by 12.08% to $3.64. The company's market cap stands at $55.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GELS

KLTO

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

OCEA

SION

SXTC

VINC

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock moved upwards by 27.2% to $2.57 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.9 million. </li>
<li>Quad/Graphics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QUAD#NYSE">QUAD</a>) stock moved upwards by 18.41% to $5.98. The company's market cap stands at $313.0 million. </li>
<li>TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) stock moved upwards by 9.62% to $0.82. The company's market cap stands at $38.8 million. </li>
<li>Haoxin Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HXHX#NASDAQ">HXHX</a>) stock increased by 8.52% to $1.91. The company's market cap stands at $26.2 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) shares moved upwards by 7.4% to $1.16. The company's market cap stands at $140.2 million. </li>
<li>Energy Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERII#NASDAQ">ERII</a>) shares moved upwards by 7.24% to $15.69. The market value of their outstanding shares is at $862.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mobile Infrastructure (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) shares decreased by 15.6% to $3.4 during Tuesday's pre-market session. The company's market cap stands at $144.8 million. </li>
<li>Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) stock declined by 9.85% to $479.0. The market value of their outstanding shares is at $69.3 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) shares decreased by 8.99% to $8.61. The market value of their outstanding shares is at $163.4 million. </li>
<li>Swvl Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWVL#NASDAQ">SWVL</a>) stock decreased by 6.74% to $2.7. The company's market cap stands at $28.9 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) stock declined by 6.43% to $0.35. The company's market cap stands at $27.8 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares fell 6.39% to $0.1. The company's market cap stands at $13.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Mobile Infrastructure Corporation Common Stock

BEEP

ERII

FORR

GPUS

HTCO

HXHX

LGCL

QUAD

SWVL

TPIC

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

New York, NY, April 22, 2025 (GLOBE NEWSWIRE) -- Mixed Martial Arts Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) ("MMA.INC" or the "Company"), a pioneering technology company seeking to aggregate and drive participation in combat sports today announced the appointment of Aaron Links as Chief Financial Officer, effective July 13, 2025, or such earlier date as agreed with the company.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;
Links will succeed Neale Java, who will remain with the Company through till July 13, 2025 to support a smooth transition before pursuing new opportunities.

Management

Mixed Martial Arts Group Appoints Aaron Links As CFO Succeeding Neale Java, Effective July 13, 2025

<h3>Gainers</h3>
<ul>
<li>eGain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGAN#NASDAQ">EGAN</a>) shares increased by 20.4% to $5.49 during Tuesday's pre-market session. The company's market cap stands at $154.4 million. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) shares rose 13.84% to $0.45. The company's market cap stands at $8.3 million. </li>
<li>Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) stock increased by 13.14% to $37.62. The market value of their outstanding shares is at $2.5 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) shares moved upwards by 12.44% to $5.24. The company's market cap stands at $535.8 million. </li>
<li>8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) shares rose 11.09% to $1.82. The company's market cap stands at $239.9 million. </li>
<li>Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) stock rose 10.11% to $2.94. The market value of their outstanding shares is at $298.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Schmid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHMD#NASDAQ">SHMD</a>) shares fell 17.8% to $2.41 during Tuesday's pre-market session. The company's market cap stands at $103.7 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) stock fell 12.76% to $1.3. The company's market cap stands at $6.3 million. </li>
<li>Fatpipe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATN#NASDAQ">FATN</a>) shares fell 12.42% to $9.1. The market value of their outstanding shares is at $124.8 million. </li>
<li>Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) shares decreased by 8.94% to $5.71. The company's market cap stands at $64.1 million. </li>
<li>E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) stock decreased by 7.86% to $1.76. The company's market cap stands at $544.4 million. </li>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares declined by 7.16% to $0.19. The market value of their outstanding shares is at $5.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Jin Medical International

Jin Medical International (ZJYL) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL